HK Stock Market Move | 3SBIO (01530) rose more than 3%, institutions are optimistic about the overseas high sales of SSGJ-707 and other pipeline assets rising potential.

3SBIO (01530) rose more than 3%, as of the time of publication, it has risen by 1.76%, to 23.1 Hong Kong dollars, with a turnover of 3.84 billion Hong Kong dollars. UBS Group AG released a research report pointing out that 3SBIO's core products target hematology and autoimmune diseases. The bank believes that Pfizer Inc.'s record-breaking $6.15 billion licensing agreement for SSGJ-707 (PD-1/VEGF bispecific antibody) reflects recognition of 3SBIO's strong research and development capabilities. In addition, the bank is optimistic about the overseas peak sales of SSGJ-707 and the rising potential of other pipeline assets, predicting that 3SBIO's revenue and net profit compound annual growth rates from 2024 to 2034 will be 11.7% and 12.1%, respectively. Key catalysts include the potential for SSGJ-707 data updates in the second half of 2025; recognition of upfront payment revenues in the third quarter; and the initiation of overseas clinical trials for SSGJ-707. BOCOM INTL believes that 3SBIO's existing core product competition landscape is favorable, and its sales performance is expected to continue to exceed expectations. Its injectable drug "Tebi-Au" is currently the only specific platelet-reducing drug approved globally for CIT indications, and is optimistic about its potential to continue to replace IL-11 class competitors. At the same time, the likelihood of generic drugs being listed in the short to medium term is small, with limited pricing pressure. It is expected that 3SBIO's product sales compound annual growth rate (CAGR) from 2024 to 2026 will reach 11%, and the long-term sales peak will reach 7 billion yuan.